Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study

References

• Bou Zerdan M, Ghorayeb T, Saliba F, et al. Triple negative breast cancer: updates on classification and treatment in 2021. Cancers (Basel). 2022;14(5):1253. doi: 10.3390/cancers14051253
   PubMed Web of Science ®Google Scholar
• Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer. 2021;124(1):13–26. doi: 10.1038/s41416-020-01161-4
   PubMed Web of Science ®Google Scholar
• Han HS, Vikas P, Costa RLB, et al. Early-stage triple-negative breast cancer journey: beginning, end, and everything in between. Am Soc Clin Oncol Educ Book. 2023;43(43):e390464. doi: 10.1200/EDBK_390464
   PubMedGoogle Scholar
• Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275–1281. doi: 10.1200/JCO.2007.14.4147
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–1804. doi: 10.1200/JCO.2011.38.8595
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172. doi: 10.1016/S0140-6736(13)62422-8
   PubMed Web of Science ®Google Scholar
• Marra A, Curigliano G. Adjuvant and neoadjuvant treatment of triple-negative breast cancer with chemotherapy. Cancer J. 2021;27(1):41–49.
   PubMed Web of Science ®Google Scholar
• Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–2159. doi: 10.1056/NEJMoa1612645
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–2743. doi: 10.1056/NEJMoa064320
   PubMed Web of Science ®Google Scholar
• Lluch A, Barrios CH, Torrecillas L, et al. Phase III trial of adjuvant capecitabine after Standard Neo-/Adjuvant Chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol. 2020;38(3):203–213. doi: 10.1200/JCO.19.00904
   PubMed Web of Science ®Google Scholar
• Zujewski JA, Rubinstein L. CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data. NPJ Breast Cancer. 2017;3(1):27. doi: 10.1038/s41523-017-0029-3
   PubMedGoogle Scholar
• Gennari A, Andre F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–1495. doi: 10.1016/j.annonc.2021.09.019
   PubMed Web of Science ®Google Scholar
• Guven DC, Yildirim HC, Kus F, et al. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment. Expert Rev Anticancer Ther. 2023;23(10):1049–1059.
   PubMed Web of Science ®Google Scholar
• Lin L, Sirohi D, Coleman JF, et al. American Society of Clinical Oncology/College of American pathologists 2018 focused update of breast cancer HER2 FISH testing GuidelinesResults from a national reference laboratory. Am J Clin Pathol. 2019;152:479–485. doi: 10.1093/ajcp/aqz061
   PubMedGoogle Scholar
• Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–181. doi: 10.1016/S1053-4296(03)00031-6
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncol. 2017;3:793–800. doi: 10.1001/jamaoncol.2016.6120
   PubMed Web of Science ®Google Scholar
• Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009;360(20):2055–2065. doi: 10.1056/NEJMoa0810266
   PubMed Web of Science ®Google Scholar
• Wang X, Wang SS, Huang H, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA. 2021;325(1):50–58. doi: 10.1001/jama.2020.23370
   PubMed Web of Science ®Google Scholar
• Iqbal J, Ginsburg O, Rochon PA, et al. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165–173. doi: 10.1001/jama.2014.17322
   PubMed Web of Science ®Google Scholar
• Di Lisa FS, Krasniqi E, Pizzuti L, et al. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study. Front Oncol. 2023;13:1152123. doi: 10.3389/fonc.2023.1152123
   PubMed Web of Science ®Google Scholar
• Dulgar O, Oven BB, Atci MM, et al. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022;22(7):773–780. doi: 10.1080/14737140.2022.2076670
   PubMed Web of Science ®Google Scholar
• Saifi O, Chahrour MA, Li Z, et al. Is breast conservation superior to mastectomy in early stage triple negative breast cancer? Breast. 2022;62:144–151. doi: 10.1016/j.breast.2022.02.006
   PubMed Web of Science ®Google Scholar
• Onitilo AA, Engel JM, Stankowski RV, et al. Survival comparisons for breast conserving surgery and mastectomy revisited: community experience and the role of radiation therapy. Clin Med Res. 2015;13:65–73. doi: 10.3121/cmr.2014.1245
   PubMed Web of Science ®Google Scholar
• Carvalho HA, Villar RC. Radiotherapy and immune response: the systemic effects of a local treatment. Clinics (Sao Paulo. 2018;73:e557s. doi: 10.6061/clinics/2018/e557s
   Google Scholar
• Zhang M, Sun H, Zhao S, et al. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. Oncotarget. 2017;8:31347–31354. doi: 10.18632/oncotarget.15532
   PubMedGoogle Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821. doi: 10.1056/NEJMoa1910549
   PubMed Web of Science ®Google Scholar
• Ishitsuka H, Shimma N, Horii I. Discovery and development of novel anticancer drug capecitabine. Yakugaku Zasshi. 1999;119(12):881–897. doi: 10.1248/yakushi1947.119.12_881
   PubMed Web of Science ®Google Scholar
• Powell SN, Kachnic LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene. 2003;22(37):5784–5791. doi: 10.1038/sj.onc.1206678
   PubMed Web of Science ®Google Scholar
• Li Y, Zhou Y, Mao F, et al. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis. Breast Cancer Res Treat. 2020;179(3):533–542. doi: 10.1007/s10549-019-05513-4
   PubMed Web of Science ®Google Scholar
• Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394–2405. doi: 10.1056/NEJMoa2105215
   PubMed Web of Science ®Google Scholar